NasdaqGM - Nasdaq Real Time Price USD

Amicus Therapeutics, Inc. (FOLD)

6.43
+0.48
+(8.07%)
At close: May 16 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
543,141
528,295
399,356
329,233
305,514
Cost of Revenue
51,074
52,943
37,326
38,599
34,466
Gross Profit
492,067
475,352
362,030
290,634
271,048
Operating Expense
444,279
441,288
435,524
495,060
470,968
Operating Income
47,788
34,064
-73,494
-204,426
-199,920
Net Non Operating Interest Income Expense
-43,938
-44,191
-43,071
-34,095
-31,962
Other Income Expense
-7,068
-18,629
-33,536
-3,518
-9,672
Pretax Income
-3,218
-28,756
-150,101
-242,039
-241,554
Tax Provision
26,155
27,350
1,483
-5,471
8,906
Net Income Common Stockholders
-29,373
-56,106
-151,584
-236,568
-250,460
Diluted NI Available to Com Stockholders
-29,373
-56,106
-151,584
-236,568
-250,460
Basic EPS
-0.09
-0.18
-0.51
-0.82
-0.92
Diluted EPS
-0.09
-0.18
-0.51
-0.82
-0.92
Basic Average Shares
305,577.05
304,380.50
295,164.52
289,057.20
271,421.99
Diluted Average Shares
305,577.05
304,380.50
295,164.52
289,057.20
271,421.99
Total Operating Income as Reported
44,645
24,876
-77,211
-212,120
-206,434
Total Expenses
495,353
494,231
472,850
533,659
505,434
Net Income from Continuing & Discontinued Operation
-29,373
-56,106
-151,584
-236,568
-250,460
Normalized Income
-27,487.20
-48,847.48
-137,640.50
-229,027.88
-245,517.17
Interest Income
4,679
5,407
7,078
3,024
509
Interest Expense
48,617
49,598
50,149
37,119
32,471
Net Interest Income
-43,938
-44,191
-43,071
-34,095
-31,962
EBIT
45,399
20,842
-99,952
-204,920
-209,083
EBITDA
53,629
29,389
-92,079
-199,578
-202,874
Reconciled Cost of Revenue
51,074
52,943
37,326
38,599
34,466
Reconciled Depreciation
8,230
8,547
7,873
5,342
6,209
Net Income from Continuing Operation Net Minority Interest
-29,373
-56,106
-151,584
-236,568
-250,460
Total Unusual Items Excluding Goodwill
-3,143
-9,188
-17,650
-7,694
-6,771
Total Unusual Items
-3,143
-9,188
-17,650
-7,694
-6,771
Normalized EBITDA
56,772
38,577
-74,429
-191,884
-196,103
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,257.20
-1,929.48
-3,706.50
-153.88
-1,828.17
12/31/2021 - 5/31/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PTCT PTC Therapeutics, Inc.
46.01
+1.54%
 
AGIO Agios Pharmaceuticals, Inc.
29.18
+3.26%
 
RARE Ultragenyx Pharmaceutical Inc.
35.61
+2.21%
 
BMRN BioMarin Pharmaceutical Inc.
59.27
+1.72%
 
ALNY Alnylam Pharmaceuticals, Inc.
285.31
+0.67%
 
RYTM Rhythm Pharmaceuticals, Inc.
59.93
-0.42%
 
LEGN Legend Biotech Corporation
27.78
+0.33%
 
CLDX Celldex Therapeutics, Inc.
20.45
+1.74%
 
KPTI Karyopharm Therapeutics Inc.
5.32
-2.21%
 
CYTK Cytokinetics, Incorporated
31.00
+3.89%